Home Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
 

Keywords :   


Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results

2013-02-01 13:00:00| Merck.com - Corporate News

Dateline City:  WHITEHOUSE STATION, N.J. 2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46 2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact from Foreign Exchange Full-Year and Fourth-Quarter Double-Digit Global Sales Growth for JANUVIA, JANUMET, GARDASIL, VICTRELIS and ZOSTAVAX Offset the Decline in SINGULAIR Sales Following Patent Expiry in the United States Provides Update on Odanacatib Program; Now Anticipates Filing in 2014 2013 Full-Year Non-GAAP EPS Target of $3.60 to $3.70, Excluding Certain Items; GAAP EPS Range of $2.03 to $2.26 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012. Language:  English Contact HTML:  MerckMedia Contacts:Ron Rogers, 908-423-6449Steve Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: results financial announces merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.11EX ORIGINAL COLOR ED
28.11Le Sserafim EASY 9
28.11Hero Belief 1/6
28.11DualSense PS5
28.11 3×35
28.11PSA10 VMAX SA HR
28.11 S-01 00X acrospeed
28.11 Bernard Haitink The Philips Years
More »